A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

NCT06323174 · Completed

Last updated 2026-05-28

This study is testing how well the medication CagriSema lowers blood sugar and body weight in adults with type 2 diabetes who manage their condition through diet and exercise, compared to a placebo.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 189 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-03 · est. completion 2025-12

Where 50 sites · China, Hungary, Italy, Poland, Saudi Arabia, Serbia, United States

What this study is testing ClinicalTrials.gov NCT06323174 ↗

Description as written by the study sponsor.

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Treatments tested

Cagrilintide Drug

Participants will receive once-weekly cagrilintide subcutaneously.
Semaglutide Drug

Participants will receive once-weekly semaglutide subcutaneously.
Placebo Drug

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Main thing measured	Change in glycated haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06323174 ↗